Cargando…
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
AIM: Assess the pharmacodynamics of lixisenatide once daily (QD) versus liraglutide QD in type 2 diabetes insufficiently controlled on metformin. METHODS: In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisen...
Autores principales: | Kapitza, C, Forst, T, Coester, H-V, Poitiers, F, Ruus, P, Hincelin-Méry, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3752965/ https://www.ncbi.nlm.nih.gov/pubmed/23368510 http://dx.doi.org/10.1111/dom.12076 |
Ejemplares similares
-
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen, Andreas B, et al.
Publicado: (2013) -
Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
por: Ahrén, Bo, et al.
Publicado: (2013) -
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
por: Johansen, Pierre, et al.
Publicado: (2020) -
The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
por: Bain, Stephen C.
Publicado: (2014) -
A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
por: Alshali, Khalid Z., et al.
Publicado: (2016)